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The cytotoxic T-lymphocyte response to wild-type simian virus 40 large tumor antigen (Tag) in C57BL/6
(H2b) mice is directed against three H2-Db-restricted epitopes, I, II/III, and V, and one H2-Kb-restricted
epitope, IV. Epitopes I, II/III, and IV are immunodominant, while epitope V is immunorecessive. We investi-
gated whether this hierarchical response was established in vivo or was due to differential expansion in vitro
by using direct enumeration of CD81 T lymphocytes with Tag epitope/major histocompatibility complex class
I tetramers and intracellular gamma interferon staining. The results demonstrate that epitope IV-specific
CD81 T cells dominated the Tag-specific response in vivo following immunization with full-length Tag while
CD81 T cells specific for epitopes I and II/III were detected at less than one-third of this level. The immuno-
recessive nature of epitope V was apparent in vivo, since epitope V-specific CD81 T cells were undetectable
following immunization with full-length Tag. In contrast, high levels of epitope V-specific CD81 T lymphocytes
were recruited in vivo following immunization and boosting with a Tag variant in which epitopes I, II/III, and
IV had been inactivated. In addition, analysis of the T-cell receptor b (TCRb) repertoire of Tag epitope-specific
CD81 cells revealed that multiple TCRb variable regions were utilized for each epitope except Tag epitope
II/III, which was limited to TCRb10 usage. These results indicate that the hierarchy of Tag epitope-specific
CD81 T-cell responses is established in vivo.
Immunity to the large tumor antigen (Tag) of simian virus 40
(SV40) in C57BL/6 mice is characterized by the development
of CD81 T lymphocytes restricted by both H2-Db and H2-Kb
and directed toward multiple epitopes within the Tag (54).
Four distinct H2b-restricted CD81 T-lymphocyte epitopes,
epitopes I, II/III, IV, and V, have been identified and precisely
mapped within SV40 Tag. Epitope IV, Tag residues 404 to 411,
is H2-Kb restricted (42, 52). Epitopes I (residues 206 to 215),
II/III (residues 223 to 231), and V (residues 489 to 497) are
restricted by H2-Db (23, 34, 50, 52). An immunological hierar-
chy has been demonstrated among these four epitopes within
Tag. Immunization of C57BL/6 mice with SV40, SV40 Tag-
transformed cells, or a recombinant vaccinia virus (rVV) which
encodes the full-length Tag leads to the induction of cytotoxic
T lymphocytes (CTL) specific for epitopes I, II/III, and IV (26,
41, 51). Frequency estimates from limiting-dilution analysis of
splenic lymphocytes obtained 9 days after immunization with
SV40 Tag-transformed cells revealed that epitope IV-specific
CTL represent 1 in 14,000 splenocytes while epitope I and
II/III-specific CTL were less abundant (1 in 67,000) and
epitope V-specific CTL were undetectable (41).
Although epitope V-specific CTL are not detected following
immunization with full-length SV40 Tag, immunization with
syngeneic cells carrying inactivating mutations or deletions in
Tag epitopes I, II/III, and IV leads to the induction of epitope
V-specific CTL (41, 50). Accordingly, epitope V has been char-
acterized as immunorecessive. Additional strategies which en-
hance the immunogenicity of epitope V include immunization
with rVVs which express epitope V as a minigene linked to a
secretory signal sequence (ES) or in which the epitope V
sequence is inserted into a nonimmunogenic murine self pro-
tein, dihydrofolate reductase (26). Precise mechanisms which
control the immunorecessive nature of epitope V from within
the Tag are not known, although the epitope V peptide forms
unstable complexes with H2-Db molecules, may be degraded
rapidly during antigen processing, and is located between
flanking sequences in the Tag, which may limit antigen pro-
cessing (26, 40).
In this study, we analyzed the hierarchy of Tag-specific
CD81 T lymphocyte responses by using direct methods in light
of recent studies which have suggested that traditional cyto-
toxicity-based analyses, which require in vitro restimulation,
can substantially underestimate the frequencies of pathogen-
specific T lymphocytes (14, 33, 39). Therefore, we investigated
the hierarchy, persistence, and T-cell receptor b (TCRb) di-
versity of Tag epitope-specific CD81 T lymphocytes by using
major histocompatibility complex (MHC) class I tetramers or
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intracellular gamma interferon (IFN-g) accumulation follow-
ing immunization of C57BL/6 mice with infectious SV40, Tag-
expressing syngeneic cells, or rVVs expressing full-length Tag
or the individual Tag epitopes. The rationale for the use of
three different vehicles to deliver Tag to the immune system
was that potentially different modes of antigen presentation of
Tag might result in quantitative differences in the Tag epitope-
specific CD81 T-lymphocyte responses. Tag delivered by trans-
formed cells sensitizes CD81 T lymphocytes by cross-priming
due to a lack of costimulatory molecules (29), whereas infec-
tion with live SV40 or rVVs may target a variety of cells
including antigen presenting cells (24, 37, 38).
The results of direct ex vivo analysis of Tag epitope-specific
CD81 T lymphocytes support the establishment of a hierar-
chical relationship in vivo in which IV . I . II/III . V.
Epitope IV-specific CD81 T lymphocytes dominated following
immunization of C57BL/6 mice with Tag-transformed cells,
SV40, or rVV-941T, which express full-length Tag. Epitope
V-specific CD81 T lymphocytes remained undetectable follow-
ing immunization with full-length Tag but were recruited to
dramatically increased levels in vivo by immunization and
boosting with transformed cells which express the epitope I-,
II/III-, and IV-deficient Tag derivative. In addition, TCRb
repertoire analysis of Tag epitope-specific CD81 T cells indi-
cated a lack of correlation between the amount of TCRb
diversity observed and the hierarchy of the CD81 T-cell re-
sponse.
MATERIALS AND METHODS
Animals. Male or female C57BL/6 (H-2b) mice (4 to 6 weeks old) were
purchased from The Jackson Laboratory (Bar Harbor, Maine) and routinely
used between the ages of 7 and 12 weeks. All mice were maintained in the animal
facility at Pennsylvania State University College of Medicine (Hershey, Pa.).
Cell lines and viruses. SV40-transformed B6/WT-19 cells have been described
previously (45). B6/T116A1 cells were generated by calcium phosphate-mediated
transfection of mouse embryo fibroblasts with plasmid pSLM361-11 as described
previously (41). Plasmid pSLM361-11 was generated by site-directed mutagen-
esis of plasmid pLM247 (41) using the Altered Sites mutagenesis procedure
(Promega Corp., Madison, Wis.). B6/T116A1 cells express a Tag derivative in
which epitopes I (residues 207 to 215) and II/III (residues 223 to 231) are deleted
and epitope IV is inactivated by alanine substitution of residues 406, 408, and
411. B6/T122B1 cells express a Tag derivative in which all four determinants (I,
II/III, IV, and V) have been inactivated by virtue of alanine substitutions to
critical MHC class I anchor residues (N210A, N227A, F408A, and N493A).
Plasmid pLMTS364-1 was used to establish the B6/T122B1 cells and was derived
from pSelect-ESV-1 by site-directed mutagenesis as described (41). B6/T122B1
cells are not specifically lysed by SV40 Tag-specific CTL clones or Tag-specific
bulk CTL (data not shown). RMA cells have been described previously (36).
The construction and use of rVVs which express SV40 Tag or Tag epitope
minigenes have been described previously (6, 26). SV40 strain VA45-54 was used
in these studies (53).
CTL clones. The SV40 Tag-specific CTL clones K-11, K-19, Y-4, and H-1 have
been described previously (15, 41, 50, 51). Conditions for culture and use of these
CTL clones have been described previously (41). CTL clones ESV-F8 and
ESV-F9 were derived by limiting-dilution cloning from an epitope V-specific
CTL line. Epitope V-specific CTL lines were established by repeated subculture
of splenocytes obtained from C57BL/6 mice immunized with the epitope V-
minigene expressing rVV strain rVV-ES-V (26) in the presence of recombinant
human interleukin-2 (Amgen) and irradiated B6/K-3,1,4 cells essentially as de-
scribed previously (41, 50). Epitope IV-specific CTL clones 15Bb/w-C7 and
15Bb/w-C18 were derived by limiting-dilution cloning from an epitope IV-spe-
cific CTL line generated by immunization of C57BL/6 mice with B6/T15Bb cells
which express a Tag derivative from which epitopes I, II/III, and V have been
deleted (41). The epitope IV-specific CTL line was established by repeated
subculture in the presence of recombinant human interleukin-2 and irradiated
B6/WT-19 cells essentially as described previously (51).
Induction of SV40 Tag-specific CTL and generation of bulk CTL. Tag-trans-
formed H2b cell lines were cultured as described previously (26) and harvested by
trypsinization prior to use in immunization or cytotoxicity assays. For studies
involving direct ex vivo staining of Tag-specific splenic CD81 cells, groups of
three to five C57BL/6 mice were routinely immunized with 4 3 107 to 5 3 107
Tag-transformed cells by the intraperitoneal route. Subsequent boosting with
Tag-transformed cells was done by the same method at the indicated times.
C57BL/6 mice were immunized in the hind footpads with 3 3 106 PFU of
SV40 strain VA45-54 in 50 ml of phosphate-buffered saline (PBS) as described
previously (43). Immunization of C57BL/6 mice with rVVs which express SV40
Tag or individual Tag CTL epitopes was performed as described previously (26).
C57BL/6 mice were immunized intravenously through the tail vein with 107 PFU
of rVV in 0.2 ml of phosphate buffered saline containing 0.1% bovine serum
albumin.
To generate bulk CTL, 107 erythrocyte-depleted splenocytes (or popliteal
lymphocytes) were combined with 5 3 105 gamma-irradiated (10,000 rads) Tag-
transformed fibroblasts and cultured for 5 or 6 days at 37°C in 5% CO2 in 12-well
plates (Costar, Cambridge, Mass.) containing 4 ml of RPMI 1640 supplemented
with 10% fetal bovine serum (HyClone, Ogden, Utah), 100 U of penicillin per
ml, 100 mg of streptomycin per ml, 2 mM L-glutamine, and 50 mM 2-mercapto-
ethanol as described previously (26).
Cytotoxicity assays. Cytotoxicity assays were used to verify the presence of
SV40 Tag-specific CTL in splenic or lymph node-derived cell populations fol-
lowing in vitro restimulation with gamma-irradiated Tag-transformed cells. Lysis
of Tag-transformed or peptide-pulsed target cells by C57BL/6-derived, second-
ary in vitro-restimulated lymphocytes was measured by using a standard 51Cr
release assay as previously described (26).
Production of MHC class I tetramers. Synthetic peptides used for tetramer
construction were synthesized in the Macromolecular Core Facility of the Penn-
sylvania State University College of Medicine as described previously (41). Pep-
tides were used for tetramer construction without further purification; these
were Tag epitope I (SAINNYAQKL), epitope II/III (SKGVNKEYL [C223S]),
epitope IV (VVYDFLKL [C411L]), epitope V (QGINNLDNL), DbN5 peptide
(SMIKNLEYM), and herpes simplex virus type 1 (HSV-1) gB peptide (SSIEF
ARL) (5, 7, 23, 27, 34, 41, 42, 50, 51). Underlined residues indicate substitutions
which were incorporated to avoid potential problems with cysteine oxidation.
Substituted peptides were found to sensitize targets for lysis by appropriate SV40
Tag-specific CTL clones and bulk Tag-specific CTL either as well as or better
than did peptides corresponding to the wild-type Tag epitopes (data not shown).
For tetramer production, plasmids encoding MHC class I heavy-chains in-
cluded pET23aH2Db-BSP (39) (H2-Db heavy chain [JA4 plasmid generously
provided by J. Altman, Emory University]) or pET3aH2Kb-BSP (H2-Kb a1 and
a2 domains with H-2Db a3 domain [this study]). pET3aH2Kb-BSP encodes a
fusion construct in which residues 1 to 236 of the H2-Kb heavy chain and 237 to
284 of the H2-Db (a3 domain) heavy chain are fused and appended with the
BirA signal peptide (BSP) (47). Only residue 260 differs between H2-Kb and
H2-Db within the exchanged region (residues 237 to 284); position 260 is occu-
pied by His in H2-Kb and Arg in H2-Db (46). Since amino acid residue 260 is not
known to make intradomain or interdomain interactions, the fusion construct of
H2-Kb with the latter half of the H2-Db a3 domain should not affect its structure
or function (31). Plasmids encoding b2-microglobulin (b2m) were pET3a-bob2m
(bovine b2m) and pET3a-hub2m (both kindly provided by D. Shields and R.
Ribaudo, then of the National Institute of Allergy and Infectious Diseases). All
plasmids were separately introduced into Escherichia coli strain BL21 (DE3), and
subunit production was induced with 1 mM isopropyl-b-D-thiogalactopyranoside
as described previously (4).
H2-Db and H2-Kb heavy-chain subunits and b2m were extracted from inclu-
sion bodies formed in E. coli essentially as described previously (3, 12). b2m
(human or bovine) inclusion bodies (27 mg) were dissolved in 8 M urea and
folded by dialysis against three to four changes of folding buffer (100 mM Tris-Cl
[pH 8.0], 2 mM EDTA, 400 mM L-arginine, 0.5 mM oxidized glutathione [Sigma,
St. Louis, Mo.]) at 4°C before being combined with heavy chain and peptide.
Heavy-chain (H2-Db or H2-Kb) inclusion bodies dissolved in 8 M urea were
combined with prefolded b2m (bovine for H2-Db tetramers; human for H2-Kb
tetramers) and synthetic peptide (;1:1:60 molar ratio [70, 26, and 60 mg, re-
spectively]) in 1 liter of folding buffer containing 5 mM reduced glutathione
(Sigma). Folding-reaction mixtures were concentrated by ultrafiltration in a
stirred cell over a PM10 membrane (Amicon Inc., Beverly, Mass.) under a
pressurized ultrapure nitrogen atmosphere. The concentrate was purified by gel
filtration (Sephacryl S100HR HiPrep 26/60; Amersham Pharmacia Biotechnol-
ogy, Piscataway, N.J.). The yield of folded complexes was estimated by the
bicinchoninic acid method (Pierce, Rockford, Ill.) and routinely ranged between
6 and 15% based on the starting protein amounts. Folded complexes were
biotinylated enzymatically with biotin protein ligase (Avidity, Boulder, Colo.) as
described previously (3). Biotinylated class I monomers were then polymerized
in the presence of R-phycoerythrin (R-PE)-conjugated streptavidin (Molecular
Probes, Eugene, Oreg.) at a 4:1 molar ratio. The concentration of tetrameric
complexes was adjusted by centrifugation over Microcon YM-100 filters (Ami-
con) and dilution with PBS. Tetramers were stored at 4°C.
FACS analysis of tetramer-stained lymphocytes. Splenic lymphocytes or bulk
CTL were washed twice in fluorescence-activated cell sorter (FACS) buffer (PBS
supplemented with 2% [vol/vol] fetal bovine serum and 0.1% [wt/vol] sodium
azide), resuspended at 2 3 107 cells per ml in FACS buffer, and incubated in the
presence of rat anti-mouse CD16/CD32 (33 mg/ml [FC Block; Pharmingen]) and
unconjugated streptavidin (33 mg/ml) (Molecular Probes) for 1 h on ice. Cells
were diluted to 14 ml with FACS buffer, pelleted, and resuspended to 2 3 107
cells per ml in ice-cold FACS buffer. Aliquots (100 ml) were added to ice-cold
microcentrifuge tubes containing 2 ml each of tetramers and antibodies, at which
time all the components were combined and mixed briefly by vortexing. Suspen-
sions were incubated on ice for at least 1 h with intermittent mixing. Staining
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suspensions were diluted into 4 ml of FACS buffer, pelleted, washed with 4 ml of
FACS buffer, pelleted, and resuspended in 0.1 ml of PBS containing 2% (wt/vol)
paraformaldehyde. Samples were analyzed promptly on a Becton Dickson
FACScan instrument using CELLQuest software. Routinely, 1 3 105 to 2 3 105
cells were analyzed for tetramer-staining analysis of ex vivo splenic populations
while 1 3 104 to 5 3 104 cells were collected for analysis of bulk-cultured CTL
or CTL clones. In instances where staining with unrelated control tetramers is
not shown, background staining was accounted for by subtracting the number of
CD81 cells which stained with a control tetramer from the number of CD81 cells
which stained specifically, as indicated in the figure legends.
All antibodies directly coupled to fluorochrome were obtained from Pharm-
ingen. Fluorescein isothiocyanate-conjugated antibodies used were directed
against CD8 (53-6.7), Vb2 (B20.6), Vb3 (KJ25), Vb4 (KT4), Vb5 (MR9.4), Vb6
(RR4-7), Vb7 (TR310), Vb8 (F23.1), Vb9 (MR10-2), Vb10 (B21.5), Vb11
(RR3-51), Vb12 (MR11-1), Vb13 (MR12-3), Vb14 (14-2), Vb17 (KJ23), CD4
(H129.19), and CD19 (1D3). PE-conjugated antibodies used included TCRb
(H57-597), CD8 (53-6.7), Vb3 (KJ25), and CD4 (H129.19). Cy-Chrome anti-
mouse CD8a (53-6.7) was used in triple-staining experiments to determine
TCRb usage.
Intracellular cytokine assay. For staining of intracellular IFN-g, spleen cells
were harvested from mice at the indicated times postimmunization. RBC-de-
pleted spleen cell suspensions were prepared, and 5 3 106 spleen cells were
incubated for 6 h at 37°C under 5% CO2 with 1 mM indicated synthetic peptides
representing Tag or control epitopes and 1 mg of brefeldin A (Sigma) per ml in
2 ml of complete RPMI 1640 containing 10% fetal bovine serum per well of a
24-well plate. Cells were stained for intracellular IFN-g using the Cytofix/Cyto-
perm Kit (Pharmingen) as specified by the manufacturer. Briefly, stimulated cells
were washed twice, Fc receptors were blocked by incubation with rat anti-mouse
CD16/CD32 (Fc Block; Pharmingen) for 20 min, and the cells were stained with
PE-labeled rat anti-mouse CD8 (Pharmingen) for 30 min. After fixation and
permeabilization for 20 min, the cells were stained with fluorescein isothiocya-
nate-labeled rat anti-mouse IFN-g (Pharmingen) or an isotype control antibody
for 30 min and then analyzed by flow cytometry as described above. The per-
centage of CD81 cells which express intracellular IFN-g was calculated by
subtracting the percentage of cells which stained nonspecifically with the isotype
control antibody from the percentage which stained specifically for IFN-g fol-
lowing stimulation with the indicated synthetic peptide. In some instances, as
indicated in the figure legends, the number of CD81 T cells which stained for
IFN-g in the presence of control peptide was additionally subtracted to deter-
mine the number of CD81 T cells which stained specifically for IFN-g.
RESULTS
Characterization of SV40 Tag-specific MHC class I tetra-
mers. To directly enumerate and characterize SV40 Tag-spe-
cific CD81 T lymphocytes, MHC class I tetramers were con-
structed using synthetic peptides corresponding to four SV40
Tag CTL epitopes (I, II/III, V, and IV). The specificities of the
tetramers were verified by testing for reactivity against SV40
Tag-specific CTL clones (Fig. 1). Due to the presence of a
COOH-terminal cysteine residue in the 8-mer epitope IV pep-
tide (VVYDFLKC), the epitope IV tetramer reagent (Kb/IV
Tet) was constructed using a C411L-substituted synthetic
epitope IV peptide (VVYDFLKL). The C411L-substituted
epitope IV peptide was recognized more efficiently than the
synthetic wild-type epitope IV peptide by the epitope IV-spe-
cific CTL clone Y-4 or by epitope IV-reactive bulk CTL (data
not shown). Kb/IV Tet specifically stained the CTL clone Y-4
(Fig. 1A, panel a) but did not stain CTL clone 2D5, which is
H2-Kb restricted and specific for residues 498 to 505 of HSV-1
gB (7). A control H2-Kb tetramer constructed using the HSV1-
gB498–505 peptide specifically stained the 2D5 CTL clone
(panel d).
Tetramers constructed with peptides corresponding to the
H2-Db-restricted epitopes I (Db/I Tet), II/III (Db/II/III Tet),
and V (Db/V Tet) were tested for specific staining of the CTL
clones K-11 (epitope I specific), K-19 (epitope II/III specific),
and H-1 (epitope V-specific) (Fig. 1B). The Db/I Tet and Db/V
Tet preparations efficiently stained the CTL clones K-11 and
H-1, respectively (Fig. 1B, panels a and k) but, as expected,
failed to stain the unrelated CTL clones. The Db/II/III Tet
reagent was constructed using the C223S-substituted epitope
II/III peptide, SKGVNKEYL, which was recognized as well as
or better than the unsubstituted II/III peptide (CKGVNK
EYL) by the CTL clone K-19 and by SV40-specific bulk CTL
in standard cytotoxicity assays (data not shown). Db/II/III Tet
showed positive but weak staining of the K-19 CTL clone
(panel f) and failed to stain the epitope I- or V-specific CTL
clones (panels b and j). A control tetramer, Db/DbN5 Tet, was
constructed for use in experiments that involved staining
of CD81 T lymphocytes with tetramers which corresponded
to the H2-Db-restricted Tag epitopes. The DbN5 peptide
(SMIKNLEYM) corresponds to an optimal H2-Db-binding se-
quence identified by Gairin et al. (27), which is immunogenic
in C57BL/6 mice (41). Db/DbN5 Tet did not stain Tag-specific
H2-Db-restricted CTL clones (panels d, h, and l) but specifi-
cally stained CD81 T cells derived from C57BL/6 mice follow-
ing immunization with an rVV expressing the DbN5 epitope
and expansion of splenocytes by in vitro restimulation (data
not shown).
Quantitation of SV40 Tag-specific CD81 lymphocytes fol-
lowing immunization with syngeneic SV40 Tag-transformed
cells. To quantitate and compare numbers of Tag-specific
CD81 T lymphocytes induced against multiple epitopes fol-
lowing Tag immunization, C57BL/6 mice were immunized with
syngeneic Tag-transformed B6/WT-19 cells and splenic lym-
phocytes were analyzed ex vivo at 9, 17, and 90 days postim-
munization. Control immunizations were performed using
syngeneic B6/T122B1 cells which express a Tag derivative con-
taining alanine substitutions, N210A, N227A, F408A, and
N493A, which alter critical MHC class I anchor residues in
epitopes I, II/III, IV, and V, respectively. B6/T122B1 cells are
not lysed by CTL clones specific for Tag epitopes I, II/III, IV,
or V or by bulk SV40 Tag-specific CTL and fail to induce CTL
specific for Tag epitopes I, II/III, IV, or V (data not shown)
following immunization of C57BL/6 mice.
Tetramers corresponding to Tag epitopes I, II/III, and IV
specifically stained CD81 lymphocytes in freshly isolated
spleen cells obtained from C57BL/6 mice 9 days after immu-
nization with the B6/WT-19 cells (Fig. 2 and 3) but not from
the B6/T122B1-immunized mice (Fig. 2A) or unimmunized
control mice (data not shown). This time point was chosen
based on previous results which revealed a peak of cytotoxicity
in freshly isolated splenic lymphocytes 8 to 10 days following
immunization (55). As expected, Kb/IV Tet stained the largest
number of CD81 lymphocytes (11.1%) (Fig. 2A), while Db/I
Tet (Fig. 2A) and Db/II/III Tet (Fig. 2B) stained lower per-
centages of CD81 lymphocytes (3.1 and 1.2%, respectively).
Consistent with results obtained with the epitope II/III-specific
CTL clones (Fig. 1B), specific staining of freshly isolated
CD81 lymphocytes with Db/II/III Tet was less intense than was
the staining observed for Db/I Tet (Fig. 2). Db/V Tet did not
detect epitope V-specific CD81 T lymphocytes in splenic pop-
ulations obtained from mice immunized with B6/WT-19 or
B6/T122B1 cells (Fig. 2A).
To demonstrate that tetramer staining correlated with the
induction of Tag-specific CTL, splenic lymphocytes were iso-
lated from mice 9 days after immunization with B6/WT-19 or
B6/T122B1 cells and were restimulated in vitro with irradiated
B6/WT-19 cells. These lymphocytes were tested for the pres-
ence of Tag tetramer-reactive CD81 T lymphocytes and the
corresponding lytic activities. As expected, the results of cyto-
toxicity assays revealed the presence of CTL specific for
epitopes I, II/III, and IV but not V (data not shown). Analysis
of the same populations using the MHC class I tetramers
revealed expansion of CD81 lymphocytes which specifically
stained with tetramers corresponding to Tag epitopes I, II/III,
and IV but not epitope V (Fig. 2).
SV40 Tag-specific CTL from the memory pool can be
readily detected following immunization with syngeneic Tag-
6924 MYLIN ET AL. J. VIROL.
FIG. 1. Specificity of MHC class I tetramers constructed using SV40 Tag epitopes or control peptides demonstrated by staining of SV40 Tag-specific CTL clones.
(A) Costaining of H2-Kb-restricted CTL clones Y-4 (Tag epitope IV specific) and 2D5 (HSV-1 gB specific) with anti-CD8 and Kb/IV Tet or Kb/gB Tet. (B) SV40
Tag-specific H2-Db-restricted CTL clones K-11 (Tag epitope I specific), K-19 (Tag epitope II/III specific), and H-1 (Tag epitope V specific) were stained with anti-CD8
and MHC class I tetramers Db/I Tet, Db/II/III Tet, Db/V Tet, or an unrelated Db tetramer, Db/DbN5 Tet.
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transformed cells by cytotoxicity assays after secondary in vitro
restimulation of splenic lymphocyte populations (28, 32). We
determined whether the tetramer reagents could be used to
directly enumerate Tag-specific CD81 lymphocytes which per-
sisted after the primary response. Splenic lymphocytes from
B6/WT-19-immunized C57BL/6 mice were analyzed addition-
ally at 17 and 90 days postimmunization using the Tag epitope
tetramer reagents. Results showing the number of Tet1 Tag-
specific T lymphocytes as a percentage of CD81 cells detected
at 9 days postimmunization (Fig. 2) were plotted as the total
number of Tet1 CD81 cells per spleen (Fig. 3) to make direct
comparisons with Tag-specific lymphocytes detected at 17 and
90 days postimmunization. CD81 lymphocytes which stained
with Db/I Tet or Kb/IV Tet remained detectable ex vivo at 17
FIG. 2. Direct enumeration by tetramer staining of SV40 Tag-specific CD81 cells induced during a primary response to Tag-transformed cell immunization. Pooled
splenocytes obtained 9 days following immunization of groups of C57BL/6 mice with transformed cells which expressed either the wild-type Tag (B6/WT-19) or an
epitope-negative substituted derivative (B6/T122B1) were stained ex vivo or following secondary in vitro restimulation (Cultured) with anti-CD8 plus Db/I Tet, Kb/IV
Tet, or Db/V Tet (A) or Db/II/III (B). Panels A and B represent two different experiments. The specificity of staining by Db/III/III Tet was verified by staining of
unimmunized C57BL/6 mice in separate experiments (results not shown). FACS dot plots represent 100,000 events (Ex vivo) or 10,000 events (Cultured).
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days postimmunization (Fig. 3A and E). Only epitope IV
CD81 lymphocytes were detected at significant levels above
background 90 days postimmunization, at 3.9 3 105 cells per
spleen (Fig. 3E). This represents approximately one-fourth the
number of epitope IV-specific CD81 T cells detected at the
peak of the response at 17 days postimmunization. Although ex
vivo tetramer staining did not detect epitope I- or II/III-specific
CD81 T lymphocytes at 90 days postimmunization (Fig. 3A
and B), epitope I- and II/III-specific (as well as IV-specific)
CD81 T lymphocytes were readily detected following second-
ary in vitro restimulation of splenocytes harvested from the
90-day B6/WT-19-immunized mice (data not shown), indicat-
ing that epitope I- and II/III-specific CD81 T cells were below
the limit of ex vivo detection by this time. As expected, epitope
V-specific CTL were not detected ex vivo (Fig. 3D) or follow-
ing secondary in vitro restimulation in the same analyses (data
not shown). Tag epitope-specific CD81 T cells were not de-
tected following immunization with B6/T122B1 cells at any
time point (Fig. 3).
Quantitation of SV40 Tag-specific CD81 lymphocytes fol-
lowing immunization with SV40. Footpad immunization with
live SV40 results in a nonpermissive infection which leads to
Tag synthesis and induction of SV40 Tag-specific CTL (43).
The Tag epitope specificities represented in CD81 T lympho-
cytes of the popliteal lymph nodes or spleen following SV40
immunization via the footpad route have not been character-
ized. Using the tetramer reagents, lymphocytes obtained from
the popliteal lymph nodes or spleens were analyzed ex vivo for
the presence of Tag-specific CD81 T lymphocytes 5 or 7 days
following footpad immunization with SV40 (Table 1). Kb/IV
Tet-staining CD81 T lymphocytes were readily detected in
lymphocytes obtained from the popliteal lymph nodes at either
5 or 7 days postimmunization and in splenic lymphocytes ob-
tained 7 days postimmunization (Table 1). Epitope I- or II/III-
FIG. 3. Induction and maintenance of Tag-specific CD81 lymphocytes following immunization with Tag-transformed cells. Groups of three C57BL/6 mice were
immunized with transformed cells which expressed either the wild-type Tag (B6/WT-19) or an epitope-negative substituted derivative (B6/T122B1). Spleens were
harvested at 9, 17, or 90 days postimmunization, and lymphocytes were pooled and analyzed by FACS analysis following staining with anti-CD8 and Tag-specific
tetramers (Db/I Tet, Db/II/III Tet, Kb/IV Tet, and Db/V Tet) or a control tetramer (Kb/gB Tet). Results are presented as the number of CD81 Tet1 cells per spleen.
Epitope II/III-specific T-cell responses were not determined at 17 days. Staining with control tetramers routinely ranged between 0.8 3 104 and 1.8 3 104 CD81 T cells
per spleen in these experiments (D).
TABLE 1. MHC class I tetramer staining and peptide-induced intracellular accumulation of IFN-g for
lymphocytes recovered from SV40-immunized C57BL/6 micea
Source of lymphocytes Time (days)postimmunization
% of CD81 cells stained with tetramer (% of CD81 cells with peptide-induced
intracellular IFN-g accumulation)b
Db/I Tet Db/II/III Tet Kb/IV Tet Db/V Tet Kb/gB Tet
Expt 1
Popliteal lymph nodes 5 1.3 (ND)c 1.5 (ND) 18.3 (ND) 1.4 (ND) 1.1 (ND)
Expt 2
Popliteal lymph nodes 7 1.1 (0.08) 0.9 (0.06) 5.4 (1.54) 0.6 (0.00) 0.5 (0.00)
Spleen 7 0.9 (0.55) 0.9 (0.27) 8.7 (6.87) 0.7 (0.01) 0.6 (0.00)
a Groups of 14 (experiment 1) or 24 (experiment 2) C57BL/6 mice were immunized with 3 3 106 PFU of SV40 strain VA45-54 in each rear footpad.
b Spleens or popliteal lymph nodes were harvested at the indicated times postimmunization, and lymphocytes were either stained with tetramers ex vivo or stimulated
with 1 mM peptide representing the Tag epitopes or a control peptide for 6 h at 37°C under 5% CO2 before being stained for intracellular IFN-g as described in
Materials and Methods.
c ND, not determined.
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specific CD81 T lymphocytes were not readily detected above
background at either time point by ex vivo staining with the
tetramer reagents (Table 1). However, the presence of small
numbers of epitope I- and II/III-specific CD81 T cells could
not be ruled out due to high levels of background staining in
this experiment, as evidenced by staining of 0.5 to 1.1% of
CD81 T cells with the control Kb/gB tetramer (Table 1). In
fact, IFN-g staining of the same populations did reveal the
presence of low levels of epitope I- and II/III-specific CD81 T
lymphocytes in the spleens but not in the popliteal lymph
nodes at 7 days postimmunization (Table 1). Secondary in vitro
restimulation and subsequent cytotoxicity assays revealed that
epitope I- and II/III-specific CTL were expanded from both
popliteal and splenic lymphocyte pools (data not shown).
Epitope V-specific CD81 T lymphocytes were not detected by
the use of tetramers or cytotoxicity assays. These results reveal
that the immunological hierarchy among Tag epitopes is exag-
gerated in favor of epitope IV in Tag-specific CD81 T-lym-
phocyte responses induced by SV40 infection compared to
immunization with Tag-transformed cells.
Quantitation of SV40 Tag-specific CD81 lymphocytes fol-
lowing immunization with rVVs expressing SV40 Tag or Tag
epitope minigenes. Immunization with SV40 Tag by systemic
infection with rVV-941T, which expresses the full-length Tag,
results in induction of CTL specific for immunodominant
epitopes I, II/III, and IV (26, 48). Since VV can replicate in the
murine host, this system provides the potential for enhanced
host cell production of Tag and Tag epitopes compared to
SV40 immunization. Groups of C57BL/6 mice were immu-
nized with rVV-941T, and splenic lymphocytes were analyzed
ex vivo at 9, 16, and 90 days postimmunization for the presence
of Tag-specific CD81 cells by tetramer staining or staining for
intracellular IFN-g accumulation (Fig. 4A to D). Consistent
with results obtained following immunization with Tag-trans-
formed cells or SV40, immunization with rVV-941T induced
levels of epitope IV-specific CD81 cells which could be readily
detected at 9 days postimmunization by either tetramer stain-
ing or IFN-g accumulation (Fig. 4D). These epitope IV-spe-
cific CD81 cells declined in number but persisted up to 90 days
postimmunization at 2.9 3 105 cells per spleen, which repre-
sents approximately 40% of the original levels detected on day
9. By comparison, epitope I-specific CD81 cells were detected
at low levels at 9 and 16 days postimmunization and repre-
sented ,104 cells by 90 days (Fig. 4A), which was the limit of
detection for these experiments. Epitope II/III-specific CD81
T cells were not detected at 9 days postimmunization, were
detected minimally at 16 days postimmunization using Db/II/
III Tet, but were not detected ex vivo at 90 days postimmuni-
zation (Fig. 4B). Epitope V-specific CD81 cells were not de-
tected in splenocytes from rVV-941T-immunized mice (Fig.
4C). Parallel cytoxicity assays of secondary in vitro-restimu-
lated splenocytes demonstrated that CTL specific for Tag
epitopes I, II/III, and IV could be expanded from rVV-941T-
immunized animals at each time point.
Comparison of the results obtained following immunization
with full-length Tag using distinct vehicles revealed that the
hierarchy among CD81 T lymphocyte responses to SV40 Tag
epitopes is exaggerated or more highly polarized under condi-
tions of Tag delivery via viruses (vv, rVV-941T, or SV40)
relative to that observed following immunization with Tag-
transformed cells. For example, the ratio of epitope IV-specific
to epitope I- and II/III-specific CD81 T cells detected 9 days
after immunization with B6/WT-19 cells (Fig. 3) is 4:1 and
10:1, respectively. The corresponding ratios in rVV-941T-
FIG. 4. Analysis of Tag-specific CD81 lymphocytes ex vivo using tetramers or anti-IFN-g antibody at various times after immunization with rVVs which express
Tag or Tag epitope minigenes. Groups of three C57BL/6 mice were immunized in the tail vein with 107 PFU of rVVs which express SV40 Tag (rVV-941T) (A to D)
or Tag epitope minigenes (I, II/III, V, or IV) appended to an endoplasmic reticulum secretory sequence (E to H). Splenocytes harvested at 9, 16, or 90 days were pooled
and analyzed by FACS analysis following staining with Tag epitope-specific MHC class I tetramers (epitopes I, II/III, V, or IV) or for accumulation of intracellular
IFN-g following a 6-h incubation in the presence of the corresponding synthetic peptides. Results are presented as the number of tetramer-stained CD81 cells per
spleen. The values shown have been corrected for nonspecific staining by subtraction of the number of CD81 cells detected with control tetramers. Likewise, the number
of CD81 IFN1 cells which stained in response to control peptide was subtracted from the number of CD81 IFN1 cells which stained in response to specific peptide.
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immunized mice (Fig. 4) are 37:1 and 700:1 for epitope I- and
II/III-specific CD81 T cells, respectively.
rVVs which express individual Tag epitopes as minigenes
efficiently induce CTL responses to the respective Tag epitopes
(6, 26). Moreover, expression of immunorecessive epitope V
as an ES-appended minigene leads to efficient induction of
epitope V-specific CTL responses (26). Direct-staining meth-
ods were used to quantitate the abundance of Tag epitope-
specific CD81 splenic lymphocytes present at 9, 16, or 90 days
after immunization with rVVs which expressed ES-linked
forms of the Tag epitope I, II/III, V, or IV (Fig. 4E to H).
Comparable numbers of Tag-specific CD81 cells were de-
tected ex vivo by staining with tetramers or for IFN-g produc-
tion by lymphocyte populations obtained at all time points
postimmunization.
Immunization with ES-linked Tag minigene-expressing re-
combinants resulted in the induction of readily detectable lev-
els of CD81 T lymphocytes for each of the respective Tag
epitopes, with epitope II/III-specific CD81 T lymphocytes be-
ing least abundant (Fig. 4F). In fact, higher levels of CD81 T
lymphocytes specific for all four epitopes were detected at each
time point relative to the levels attained following immuniza-
tion with rVV-941T (compare Fig. 4A to D with Fig. 4E to H).
rVV-ES-V immunization resulted in induction of levels of
epitope V-specific CD81 cells which were intermediate be-
tween those observed for epitopes I and II/III (Fig. 4H).
Epitope IV- and I-specific CD81 cells remained detectable at
3.4 3 105 and 2.7 3 104 cells per spleen by 3 months after
immunization with rVV-ES IV and rVV-ES I, respectively
(Fig. 4E and H). Epitope II/III- and V-specific CD81 T-cell
numbers dropped below 104 cells per spleen by 90 days postim-
munization, which was below the limit of reliable detection.
Appropriate Tag-specific CD81 T lymphocytes and CTL, re-
spectively, were detected following secondary in vitro restimu-
lation by tetramer staining and standard cytotoxicity assays at
each time point (data not shown). These results, which rely on
direct measurements of Tag-specific CD81 T lymphocytes,
show that increased numbers of Tag epitope-specific CD81 T
lymphocytes are recruited following immunization with rVV-
ES minigenes compared to those recruited following immuni-
zation with rVV-941T.
Induction and enhancement of CD81 T lymphocytes specific
for the immunorecessive epitope V in Tag. Epitope V in SV40
Tag has been characterized as immunorecessive because im-
munization with wild-type Tag fails to induce epitope V-spe-
cific CTL but immunization with syngeneic cells expressing a
Tag which lacks functional epitopes I, II/III, and IV results in
induction of epitope V-specific CTL (41, 50). Db/V Tet was
used to directly enumerate epitope V-specific CD81 cells 8
days following immunization of C57BL/6 mice with B6/T116A1
cells, which express a Tag derivative lacking epitopes I, II/III,
and IV. Db/V Tet stained 0.93% of CD81 T lymphocytes ex
vivo (Fig. 5A). Similar levels of epitope V-specific CD81 cells
were detected by staining for intracellular accumulation of
IFN-g following stimulation with the epitope V peptide (data
not shown). Epitope V-specific CD81 T lymphocytes expanded
to 19.7% of CD81 T cells following secondary in vitro restimu-
lation (Fig. 5A).
Since epitope V-specific CD81 cells could be efficiently ex-
panded in vitro by restimulation with gamma-irradiated Tag-
expressing cells (Fig. 5A), it was of interest to determine
whether the numbers of epitope V-specific CD81 lymphocytes
could be further enhanced in vivo by boosting. The results of ex
vivo measurements revealed that, indeed, a second immuniza-
tion with B6/T116A1 cells led to a dramatic increase in the
number of epitope V-specific CD81 cells (13.7% [Fig. 5B] and
25.7% [Fig. 5C]). The numbers of Db/V Tet-staining CD81
cells detected ex vivo in these experiments were equal to or
greater than the numbers routinely measured in primary re-
sponses to intact Tag for the immunodominant epitope IV
(11.3% for Kb/IV Tet [Fig. 2A]). Since epitope V-specific
CD81 T cells were expanded efficiently by this prime-and-
boost approach with B6/T116A1 cells, we determined whether
priming and boosting with syngeneic cells expressing the full-
length Tag might also increase the number of epitope V-spe-
cific CD81 T cells. The results revealed that enhanced levels of
epitope I- and IV-specific CD81 T cells were detected by
tetramer staining but that epitope V-specific CD81 cells were
not detected under the same conditions (Fig. 5C). These re-
sults indicate that with an appropriate immunization strategy,
epitope V-specific CD81 cells can be expanded to relatively
high levels in vivo.
Repertoire of TCRb usage by SV40 Tag-specific CD81 cells
in vivo. The diversity of TCRb usage by CD81 T cells respond-
ing to SV40 Tag epitopes has been largely uncharacterized. In
initial attempts to investigate the TCR repertoire used by Tag-
specific CD81 T lymphocytes, Tag-specific CTL clones were
analyzed for TCRb subunit usage by FACS analysis (Table 2).
The results revealed that CTL clones specific for epitopes I and
II/III expressed TCRb10 whereas selected epitope I- and V-
specific CTL clones expressed TCRb7. Sequence analysis con-
firmed that distinct CDR3 sequences were expressed by CTL
clones of differing epitope specificities which used similar
TCRb segments (data not shown). Curiously, all three epitope
II/III-specific CTL clones utilized TCRb10; although CTL
clones K-19 and Y-2/Y-3 were isolated in independent exper-
iments, they express identical CDR3 sequences (data not
shown). This suggested the presence of restricted TCRb usage
in the development of epitope II/III-specific CTL responses.
Epitope V-specific CTL clones utilized TCRb7, TCRb9, or
TCRb2, while epitope IV-specific CTL clones utilized TCRb9,
TCRb8, or TCRb5. These results reveal similarity and diver-
sity in TCRb usage by SV40 Tag-specific CTL clones which
were established following immunization with Tag-trans-
formed cells.
To determine whether TCRb usage by Tag-specific CTL
clones was representative of Tag-specific CD81 responses in
vivo, tetramers were used to examine the TCRb usage of Tag
epitope-specific CD81 T lymphocytes following immunization
of C57BL/6 mice with Tag-transformed cells. The results of
direct ex vivo examination of CD81 spleen cells from 9-day
B6/WT-19-immunized C57BL/6 mice using the epitope IV-
specific tetramer revealed predominant usage of TCRb5 and
TCRb8, and suggested lower, but favored, usage of TCRb9
and TCRb13 by epitope IV-specific CD81 T cells (Fig. 6A).
Due to the relatively small numbers of CD81 lymphocytes
detected by the Db/I and Db/II/III Tet reagents in primary
responses at 9 days postimmunization (Fig. 2), measurements
of TCRb usage among epitope I-, II/III-, and IV-specific
CD81 T lymphocytes were made following immunization and
secondary in vitro restimulation with syngeneic Tag-expressing
cells (B6/WT-19). The results of the TCRb usage by epitope
IV-specific CD81 T lymphocytes (CD81 Kb/IV Tet1) deter-
mined by this method (Fig. 6B) were in good agreement with
results obtained by direct ex vivo analysis of splenocytes ob-
tained 9 days following immunization (compare Fig. 6A and
B). Epitope I-specific CD81 T lymphocytes utilized TCRb7,
TCRb8, and TCRb10 (Fig. 6C), while epitope II/III-specific
CD81 T lymphocytes utilized only TCRb10 (Fig. 6D). These
results are in good agreement with the results obtained from
TCRb analysis of Tag epitope-specific CTL clones (Table 2).
Epitope V-specific CD81 T lymphocytes remain at relatively
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low levels following a single immunization with B6/T116A1
cells (epitope V-only Tag [Fig. 5A]). For TCRb analysis,
epitope V-specific CD81 T lymphocytes were expanded by
immunization, boosting, and secondary in vitro restimulation.
The results showed preferential usage of TCRb2, TCRb7, and
TCRb9 by epitope V-specific CD81 T lymphocytes (Fig. 6E).
Direct ex vivo measurements performed under similar condi-
tions also revealed preferential usage of TCRb2 and TCRb7
by epitope V-specific CD81 T lymphocytes (data not shown).
These results reveal that distinct patterns of TCRb usage char-
FIG. 5. Direct enumeration of Tag epitope V-specific CD81 cells ex vivo. (A and B) Groups of C57BL/6 mice were immunized with B6/T116A1 cells once (A)
(8-day primary) or twice (B) (1 month; 7-day boost); B6/T116A1 cells express a Tag derivative in which epitopes I, II/III, and IV have been deleted or inactivated by
alanine substitutions but epitope V has been retained. Pooled splenocytes were analyzed ex vivo or following secondary in vitro restimulation (Cultured) by FACS
following staining with tetramers specific for Tag H2-Db-restricted epitopes I or V. (C) Groups of C57BL/6 mice were immunized and boosted with either B6/WT-19
or B6/T116A1 cells after 1 or 3 months as indicated. Splenocytes were harvested after 7 days, pooled, and analyzed by FACS analysis after being stained with the
indicated tetramers. Dot plots illustrate results for 200,000 (Ex vivo) or 50,000 (Cultured) cells. Numbers shown in the upper right quadrant correspond to the
percentage of CD81 cells stained by the respective tetramer.
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acterize CD81 T-lymphocyte responses to SV40 Tag CTL
epitopes I, II/III, IV, and V.
DISCUSSION
The direct analysis of CD81 T lymphocytes from Tag-im-
munized C57BL/6 mice clearly demonstrates that immu-
nodomination by epitope IV is established in vivo. In addition,
the role of epitope V as a true immunorecessive epitope was
reinforced by the finding that epitope V-specific CD81 T cells
were undetectable by ex vivo analysis of lymphocytes from
C57BL/6 mice immunized with wild-type Tag, even following a
priming-and-boosting protocol. This indicates that epitope V-
specific T-lymphocyte responses are controlled in vivo rather
than at the level of in vitro expansion. In contrast, in the
absence of immunodomination by the other Tag epitopes,
epitope V-specific CD81 T lymphocytes were recruited in vivo
following immunization with a cell line expressing only epitope
V or an rVV-expressing epitope V as a minigene. Boosting of
the epitope V-specific response with epitope V-only cells re-
sulted in further expansion of epitope V-specific CD81 T cells
in vivo, indicating that epitope V-specific CD81 T cells can be
recruited to high levels by using an appropriate immunization
strategy.
Frequency measurements of Tag epitope-specific CD81 T
lymphocytes in Tag-immunized C57BL/6 mice obtained by
staining with epitope-specific MHC class I tetramers or by
intracellular IFN-g accumulation revealed significantly larger
numbers of epitope-specific CD81 T cells than were estimated
by limiting-dilution analysis. For example, previous estimates
of CTL precursor frequencies indicated that 1 in 14,000
splenocytes from 9-day B6/WT-19-immunized C57BL/6 mice
were specific for Tag epitope IV (41). Considering that CD81
T lymphocytes comprised roughly 10% of splenic lymphocytes,
epitope IV-specific CTL would represent approximately 1 in
1400 CD81 T cells. In contrast, the direct methods used in the
present study indicated that 11% (or ;1 in 10) of CD81 cells
were specific for Tag epitope IV. Frequencies determined for
CD81 T cells specific for Tag epitopes I (1 in 32) and II/III (1
in 82) also were approximately 100-fold higher than those
previously estimated by limiting-dilution analysis. This overall
increase in sensitivity of approximately 100-fold is in line with
similar studies in other systems (14, 25, 39, 44). Even with
improved sensitivity, however, epitope V-specific CD81 T lym-
phocytes were not detected ex vivo following immunization
with full-length Tag. It is unclear how Tag-specific CTL re-
sponses might differ if Tag were produced by a chronic viral
infection. In other commonly studied models of immunodomi-
nance, e.g., lymphocytic choriomeningitis virus, frequencies of
epitope-specific CD81 T cells can approach 1 in 3 shortly after
infection (39). This difference might be attributed to the ex-
tensive proliferation of lymphocytic choriomeningitis virus in
the spleen and lymph nodes (9) compared to the proliferative
responses generated following Tag immunization in this study.
We note that the frequency of memory T cells detected for the
immunodominant epitope IV by 90 days postimmunization
was similar following immunization with either B6/WT-19
cells, rVV-941T, and rVV-ESIV and is in line with the number
of memory T cells detected in other systems (13, 39).
Three distinct vehicles were used to immunize mice with
FIG. 6. TCRb usage by Tag-specific CD81 cells. CD81 cells were analyzed
for Tag specificity by tetramer staining and for TCRb expression by FACS
analysis. The results are presented as the percentage of CD81 Tet1 lymphocytes
stained with a TCRb-specific antibody. (A) Staining of splenocytes ex vivo from
C57BL/6 mice 9 days after immunization with B6/WT-19 cells using anti-CD8
antibody, Kb/IV Tet, and TCRb-specific monoclonal antibodies. (B to D)
Splenocytes were harvested from C57BL/6 mice immunized for 1 month with
B6/WT-19 cells and restimulated in vitro with irradiated B6/WT-19 cells for 5
days. Cells were triple stained using anti-CD8 antibody, tetramer (Kb/IV Tet [B],
Db/I Tet [C], and Db/II/III Tet [D]), and a panel of TCRb-specific antibodies
and analyzed by flow cytometry. (E) Splenocytes were harvested from C57BL/6
mice immunized with B6/T116A1 cells (1 month followed by a 7-day boost) and
restimulated in vitro with irradiated B6/WT-19 cells for 5 days. Cells were triple
stained using anti-CD8 antibody, Db/V Tet, and TCRb-specific antibodies and
analyzed by flow cytometry. The most prominent TCRb chains used are indi-
cated by the corresponding TCRb number on top of each bar. Asterisks indicate
TCRb segments used by the SV40 Tag-specific CTL clone(s) with corresponding
epitope specificity.
TABLE 2. Specificity, MHC restriction, and TCRb usage for SV40
Tag-specific CTL clones





K-11 I H-2Db 10 15
Y-1 I H-2Db 7 51
K-19 II/III H-2Db 10 15
Y-2 II/III H-2Db 10 51
Y-3 II/III H-2Db 10 51
Y-5 V H-2Db 7 50
H-1 V H-2Db 9 41
ESV-F8 V NDa 2 This study
ESV-F9 V ND 2 This study
Y-4 IV H-2Kb 9 51
15Bb/w-C7 IV ND 8 This study
15Bb/w-C18 IV ND 5 This study
a ND, MHC restriction was not formally demonstrated for these clones, al-
though they were shown to display the appropriate epitope specificities by using
peptide-pulsed targets and/or Tag epitope loss derivative cell lines.
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full-length SV40 Tag, including Tag-transformed cells, SV40,
and rVV-941T. Specific mechanisms which deliver Tag
epitopes into the MHC class I antigen-processing pathway will
probably vary for each of these vehicles due to their ability to
target different cell types and due to the use of distinct routes
of immunization. Induction of Tag-specific CTL by immuniza-
tion with Tag-transformed cells is likely to rely on re-presen-
tation, or cross-priming, of the antigen by professional antigen-
presenting cells (APCs) (29, 55). Cross-priming also may be
utilized in cases where rVV-941T or SV40 infect cells that do
not express costimulatory molecules. Tag delivery through im-
munization with SV40 or rVV-941T, however, may result in
infection of APCs which directly sensitize CD81 T cells. For
example, SV40 transforms macrophages (24, 37). SV40 estab-
lishes a nonpermissive infection in mouse cells, with the virus
cycle limited to the expression of Tag, thus inducing the pro-
liferation of infected cells which persist until they are elimi-
nated by immune mechanisms (1, 35). In contrast, VV repli-
cates and releases new virus progeny, which in turn can infect
more cells (38), resulting in increased availability of Tag.
On the other hand, immunization with Tag-transformed
cells has the potential for rapid delivery of a relatively large
amount of presynthesized Tag protein and/or preprocessed
Tag epitopes for cross-priming. In fact, immunization with
either SV40 or rVV-941T resulted in exaggeration of the im-
munodominance of epitope IV over epitopes I and II/III com-
pared to that found for immunization with B6/WT-19 Tag-
transformed cells. The requirement for host cell biosynthesis of
Tag might limit the availability of H2-Db-restricted Tag
epitopes in vivo and therefore might skew the immunodomi-
nance of Tag-specific CD81 T-cell responses in favor of
epitope IV. Although the precise mechanisms by which Tag
epitopes are derived from each vehicle are likely to differ, it is
important to note that the hierarchy observed for induction of
Tag epitope-specific CD81 cells in each case was consistent.
Thus, epitope IV-specific CD81 T lymphocytes were clearly
dominant regardless of the mode of immunization, while
epitope V-specific CD81 T lymphocytes were never detected
following immunization with wild-type Tag.
Deficiencies in antigen processing of selected T-cell epitopes
contribute to immunogenicity and rank within the immunolog-
ical hierarchy of T-cell responses (18, 58). Specific mechanisms
which might lead to the immunorecessive phenotype include
inefficient processing of the epitope from the native protein,
inefficient transport by transporters associated with antigen
processing (TAP), or relatively weak interactions with MHC
class I molecules compared to immunodominant epitopes. The
amino acid context surrounding epitope V within Tag limits
processing, presentation, and immunogenicity for at least one
test epitope (40). By extension, the results of that study imply
that the immunogenicity of epitope V may be limited by similar
constraints on processing of the epitope. In addition, epitope V
is destroyed by the proteasome when expressed as a minigene
from an rVV (26). This phenotype can be rescued by the use of
inhibitors of the proteasome, addition of alanine residues at
either terminus of the minigene, or targeting the peptide to the
endoplasmic reticulum using ES, suggesting that the epitope V
peptide is readily degraded in the cytosol. We have previously
shown that the epitope V peptide functions efficiently in TAP
assays, but it forms relatively unstable complexes with H2-Db
molecules compared to epitopes I and II/III (26). Thus, rela-
tively small numbers of Db/V complexes on the APC surface
might limit the induction of epitope V-specific CD81 T lym-
phocytes in the presence of immunodominant Tag epitope-
specific CD81 T lymphocyte responses. The number of epitope
Db/V complexes on Tag-expressing cells remains to be deter-
mined.
The abundance of a particular peptide-MHC complex, how-
ever, is not necessarily the determining factor in establishing
the hierarchy of CTL responses. In fact, Pamer and coworkers
(13, 56) have shown that the hierarchy of the CD81 T-cell
responses to three H2-Kd-restricted epitopes from Listeria
monocytogenes is inversely related to the abundance of the
epitopes. The ability of epitope V to induce the accumulation
of high levels of cognate CD81 T lymphocytes in vivo following
immunization and boosting with the epitope I-, II/III-, and
IV-deficient Tag derivative suggests that the immunorecessive
status of epitope V is not due solely to the biophysical prop-
erties of the peptide or Tag context alone. In fact, at 17 to 25%
of CD81 cells, frequencies for epitope V-specific CD81 T cells
were obtained in vivo which approximated the optimal fre-
quencies observed for epitope IV- or I-specific CD81 T cells
obtained following two immunizations with B6/WT-19 cells.
Thus, the number of CD81 T-cell precursors specific for
epitope V can readily expand under the proper circumstances,
suggesting that limitations in the response to epitope V are not
due to an inherent inability of epitope V-specific T-cell pre-
cursors to expand in vivo. Although the basis for the immuno-
recessive nature of the epitope V-specific CD81 T-lymphocyte
response remains to be determined, our results support an
important role for immunodomination by other Tag epitope-
specific CD81 T cells.
Analysis of TCRb usage has been used to estimate the
variability of epitope-specific T-lymphocyte responses. Studies
investigating the variability of the TCRb usage by T lympho-
cytes responding to immunodominant epitopes have shown
that both limited (2, 17, 19, 21, 22) and highly variable (20, 30,
57) usage can be detected, depending on the system studied. A
few studies have indicated that the TCRb usage by CTL spe-
cific for immunodominant epitopes is more diverse than the
TCRb usage by CTL specific for subdominant epitopes within
the same system (10, 16). Thus, while general conclusions
regarding the role of TCRb diversity in immunodominance
cannot be made, it remains to be determined whether the
variability of the response might contribute to immunodomi-
nance in some systems. The advent of MHC class I tetramers
and intracellular cytokine staining has made it possible to an-
alyze the TCRb repertoire of epitope-specific CD81 T cells ex
vivo or after a brief period of in vitro expansion instead of
needing multiple rounds of in vitro restimulation or relying on
the development of CTL clones. Using these approaches, anal-
ysis of TCRb usage by epitope-specific CD81 T cells indicates
that the response to immunodominant epitopes is character-
ized by overall diversity but with preferential expansion of T
cells expressing a few TCRb subunits (12, 18, 49).
Direct counting of Tag epitope-specific CD81 T lympho-
cytes by tetrameric reagents has made it possible to examine
the TCRb repertoires responding to the individual Tag
epitopes. The results of this analysis indicate that the TCRb
repertoire varied in both the identity of the predominant
TCRb subunit(s) as well as the overall diversity of TCRb
chains utilized within each response. The results obtained by
the analysis of Tag-specific CD81 populations from mice im-
munized with Tag-transformed cells or following a single pe-
riod of secondary in vitro restimulation appear to correlate
well with the results obtained by the analysis of established
Tag-specific CTL clones. Notable exceptions appear to be the
use of TCRb13 and TCRb8 in CD81 populations responsive
to epitopes IV and I, respectively. Analysis of additional CTL
clones may reveal their usage, unless expansion of CD81 lym-
phocytes expressing these TCRb is somehow limited in vitro.
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Favored usage of TCRb5 and TCRb8 by epitope IV-specific
CD81 T cells was not unique to the particular methods used
for induction or expansion, which included priming, boosting,
and in vitro restimulation with Tag-transformed syngeneic
cells. We did not observe narrowing of the CD81 response to
a particular TCRb subunit following boosting of the Tag re-
sponse as has been reported for CD81 responses to a Listeria
monocytogenes epitope (11, 12). Additionally, the fact that
epitope IV-specific CTL clones and freshly isolated epitope
IV-specific CD81 T cells utilize similar TCRb chains indicates
that in vitro cultivation did not bias the outgrowth of clones
using less frequently represented TCRb subunits from the in
vivo CD81 population as suggested for other systems (49).
TCRb usage by CD81 T lymphocytes specific for Tag epitopes
I and V was similarly diverse, suggesting that the immunore-
cessive nature of the epitope V-specific CD81 T-lymphocyte
response is not due to constraints on TCR diversity.
In contrast to the diverse TCRb repertoire utilized in re-
sponse to epitope I, IV, and V, epitope II/III-specific CD81 T
lymphocytes and CTL clones appear to utilize TCRb10 exclu-
sively. Results of CDR3 nucleotide sequence analysis revealed
identity among TCRb subunits used by epitope II/III-specific
CTL clones Y-2, Y-3, and K-19 (data not shown). Together,
these results imply that the TCRb repertoire of Tag epitope
II/III-specific CD81 T lymphocytes may be very limited. The
variability of the TCRa repertoire in this CD81 T-cell popu-
lation remains to be determined. Mechanisms which have been
suggested to limit the diversity of a specific T-cell response
include the deletion or inactivation of epitope-specific T cells
due to cross-reactivity with self antigens (19), limitations in the
efficiency with which epitopes are presented for recognition by
naive CD81 T cells (16), and a delay in the relative time of
initial antigen exposure which might limit the expansion of
antigen-specific T cells (8). It remains to be determined
whether the diversity of TCRb usage by epitope II/III-specific
CD81 T cells would be altered in the absence of ongoing
CD81 T-cell responses to epitopes I and IV or whether the
limited TCRb diversity observed for epitope II/III-specific
CD81 T cells may explain the less vigorous response to this
epitope compared to the responses to epitopes I and IV.
The results of this study clearly demonstrate that the hier-
archy of Tag epitope-specific CD81 T-cell responses is estab-
lished in vivo. Although the specific mechanisms which lead to
immunodomination in this system remain to be determined,
the advent of methods for direct detection of responding T
cells has provided powerful tools for the investigation of the
hierarchical relationships established in vivo, and their use
should further enhance our understanding of immunodomina-
tion.
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